Kevin Cady is the CEO and Founder of OnPoint Vision™, a refractive company that designs, develops & manufactures intraocular lens implants, most specifically the AccuraSee™ Intraocular Pseudophakic Contact Lens (AKA: CadyLens) designed to fine-tune the refractive error of the pseudophakic eye as well as deliver vision recovery for patients who have experienced a decline in vision due to age-related retinal pathologies. Prior to forming OnPoint Vision™, Mr. Cady joined Refocus Group in 2015 as Vice President of Marketing & Business Development. From 2011 to 2014, Mr. Cady was the Regional Business Director for WaveTec Vision Systems, where he was responsible for the marketplace expansion of the Optiwave Refractive Analysis (ORA) system to ophthalmic surgeons. Prior to joining WaveTec Vision Systems, Mr. Cady was the Area Vice President of Sales for Bausch Lomb Surgical, after the company acquired Eyeonics. Mr. Cady has over 30 years in the ophthalmic industry theatre with extensive knowledge and experience in both the development of ophthalmic pharmacologic agents and medical device product line.
Mr. Cady has a Bachelor of Science Degree in Economics from Illinois State University. He is credentialed with over 35 patents worldwide with the invention of the CadyLens, an Intraocular Pseudophakic Contact Lens (IOPCL) as well as related surgical instruments and medical devices.
Tonya Porter is independent consultant specializing in regulatory affairs, quality assurance, and clinical affairs for medical device companies. Before she started consulting in 2018, she was the Vice President of Global Regulatory Affairs & Quality Assurance at ReVision Optics, Inc. (RVO), where she was responsible for US product approvals, international product registrations, and assuring the highest quality of products are provided to the RVO customer. Ms. Porter was a member of the RVO team since 2006, and has a diverse background from product development to managing international clinical trials for ophthalmic products.
Prior to joining RVO, she served in the Division of Chemistry and Material Science in the Office of Science and Engineering Labs in the Center for Devices and Radiological Health at the U.S. Food and Drug Administration (FDA/CDRH/OSEL/DCMS).
Ms. Porter earned her BS degree in Engineering from the Harvey Mudd College, and an MS in Biomedical Engineering from the University of California, Irvine.
Louis has more than 27 years of experience as a senior financial executive with early-stage medical device companies. He was instrumental in raising more than $250 million in venture equity and debt as well as being actively involved in developing and implementing strategies for growth and maximizing shareholder value. Louis is currently serving as Chief Financial Officer of OnPoint Vision, Inc.™ and Centricity Vision, Inc., a cataract platform company.
Prior experience included serving as CFO of ReVision Optics, Inc., a corneal inlay company, serving as CFO of 3F Therapeutics, Inc., a tissue heart-valve company, acquired by ATS Medical, Inc., EndiCOR Medical, Inc., a coronary catheter company, acquired by Ev3, Inc., and SenDx Medical, Inc., a critical care diagnostic company, acquired by Radiometer. Prior to joining SenDx, Louis served as a Senior Audit Manager with Ernst & Young.
Jonathan’s experience is quite varied, with half of his career in Ophthalmic product design and development. His first experience was with the Ophthalmics division of Optical Radiation where, for 2 years, he was a project engineer developing IOL’s and manufacturing processes.
Then, after approximately 10 years as a system/project engineer in semiconductor manufacturing equipment design and development, Jonathan returned to the Ophthalmic industry as an engineer at Eyeonics, Inc for 5 years. After the acquisition of Eyeonics by Bausch & Lomb, he spent another 2 years supporting the Crystalens®, the very first accommodating intraocular lens (IOL) in Ophthalmology.
In 2010 Jonathan became an independent consultant with a full-time effort developing an IOL with CORD, LLC. As time permitted, he also has supported several small Ophthalmic startups. In 2015 he began working with Kevin Cady on the development of the novel AccuraSee™ Intraocular Pseudophakic Contact Lens (IOPCL).
Lynne Archer has over 35 years’ experience in the field of clinical research. For the past 25 years, Ms. Archer has been exclusively involved in ophthalmic clinical research. Lynne is the CEO of Eyecon clinical consulting, a small CRO dedicated to elevating novel ophthalmic technology through clinical trials with the ultimate goal of FDA approval. Prior to starting her own business in 2010 Lynne served as Vice-President, Clinical Science for Eyeonics, where she was responsible for developing and implementing the clinical strategy and was instrumental in obtaining the first FDA approved Crystalens accommodating IOL.
Prior to Eyeonics, Lynne was the Ophthalmic National Study Director for Pharmacia. While at Pharmacia Lynne was instrumental in the approval of the first FDA prostaglandin drug, Xalatan®, for the treatment of glaucoma.
Kevin L. Waltz, OD, MD is a board certified ophthalmologist with extensive experience and knowledge of advanced IOLs and optics and clinical research. He has been actively involved in broadening the clinical horizon of advanced IOLs for over twenty years. He is a long-term consultant and advisor to the industry and inventor of the technology.
Dr. Waltz is the Chairman of the Board of Directors for CAEC-Central American Eye Clinics, and the President of Ophthalmic Research Consultants.
